Your browser doesn't support javascript.
loading
Secondary Neuroendocrine Carcinoma Following High-Dose Radiotherapy for Head and Neck Cancer: Report of Two Cases.
Taggar, Amandeep S; Simpson, Roderick; Hao, Desiree; Webster, Marc; Khalil, Moosa; Lysack, John; Skarsgard, David.
Afiliação
  • Taggar AS; Radiation Oncology, Memorial Sloan-Kettering Cancer Center ; Radiation Oncology, University of Calgary/Tom Baker Cancer Center.
  • Simpson R; Department of Pathology, University of Calgary.
  • Hao D; Medical Oncology, University of Calgary.
  • Webster M; Medical Oncology, University of Calgary.
  • Khalil M; Department of Pathology, University of Calgary.
  • Lysack J; Department of Diagnostic Imaging, University of Calgary.
  • Skarsgard D; Medical Oncology, University of Calgary.
Cureus ; 8(10): e847, 2016 Oct 25.
Article em En | MEDLINE | ID: mdl-27909635
ABSTRACT
Patients treated with radiation have an increased risk of developing second cancers, of which carcinomas, sarcomas, and hematological malignancies have most commonly been reported. Neuroendocrine carcinomas (NEC) are rarely reported in patients previously treated with radiation. Two patients, who had successfully undergone chemoradiotherapy for head and neck cancers at our institution, developed secondary NEC within the radiation field more than five years after the treatment. Both patients underwent curative-intent treatment of secondary malignancies, one with chemotherapy, radiation and surgery (Case 1) and the other with chemotherapy and surgery (Case 2). Both had no evidence of disease at a short follow-up of twelve months (Case 1), and three months (Case 2) after treatment. NEC can develop post-radiotherapy; a multidisciplinary approach is necessary to successfully treat these patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article